RxDoctor Payments Data

Glenn Bryant, MD

Internal Medicine · Lima, OHNPI 1588686794

Payments from drug & device makers

$2,315in general payments, 2019–2025

Across 155 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$403
  • AstraZeneca$334
  • Vifor Pharma, Inc.$223
  • OPKO Pharmaceuticals, LLC$157
  • Abbott$143
  • Amgen$126
  • plus $929 from 23 others

What the payments were for

  • Food & beverage$2,26698%
  • Education$492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,315 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$55,844
Medicare patients
259
Services billed
853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$49,114
EliquisApixaban43$46,034
RybelsusSemaglutide22$34,110
MounjaroTirzepatide32$32,687
TrulicityDulaglutide14$24,711
FarxigaDapagliflozin Propanediol21$21,676
Tresiba Flextouch U-200Insulin Degludec20$19,461
OzempicSemaglutide14$19,332
TradjentaLinagliptin13$18,640
MyrbetriqMirabegron12$11,994
Breo ElliptaFluticasone/Vilanterol15$8,073
XareltoRivaroxaban12$6,992
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,764
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,992
Prasugrel Hcl13$4,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$33$57,39846 claims
Novo NordiskRybelsus, Ozempic$403$53,44336 claims
PfizerEliquis, Paxlovid$86$50,34754 claims
AstraZenecaFarxiga$334$21,67621 claims
Johnson & JohnsonXarelto$42$6,99212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →